Based on strengths in glycobiology, microbial biotechnology, biological system’s engineering and bio-analytics, our research group is developing innovative molecular technology to enable novel approaches to study, diagnose and treat immune-system related disease.

Nico Callewaert

Science Director
VIB Science Director since 2014
VIB Group leader since 2005
Postdoc.: ETH, Zürich, Switzerland, 2002-2005
PhD: Univ. of Ghent, Ghent, Belgium, 2002

Research areas

Medical biotechnology Systems biology

Research focus

We exploit the developed technologies for our own research interests in inflammation and immunity, in collaboration with experts within and outside of CMB. For development and exploitation of our technologies in other fields, we collaborate intensively with the biotechnology and pharmaceutical industry. At the moment, our strategic technology development focuses on microbial cell engineering as a basis for the discovery and development of novel immunomodulatory biopharmaceuticals. We are also developing new glyco-analysis tools and animal models to pursue the role of inflammation-induced lymphocyte glycosylation changes in the pathophysiology of inflammatory disease.

read more


To showcase the world-class scientific research of the Nico Callewaert Lab, you can discover their scientific papers in more detail.

more info


We are always on the lookout for highly motivated colleagues to join our team. If you are interested, please contact us.

more info


The Nico Callewaert Lab can only thrive thanks to the dedication and commitment of its people, no matter what their function or seniority.

read more


To stay up to date in rapidly developing fields, scientists regularly interact with (international) colleagues. Conferences and other (scientific) events are an excellent way to facilitate such a continent-spanning knowledge exchange.

more info


Callewaert Lab news

Antibodies you can eat: A therapeutic revolution from the Callewaert lab and collaborators


Therapeutic antibodies are being used increasingly in the clinic for the treatment of various diseases. Yet, oral to gut targeting of antibodies remains a challenge due to their incapability to survive digestion and reach gastrointestinal tissues. Now, the labs of Nico Callewaert (VIB-UGent), Ann Depicker (VIB-UGent), Henri De Greve (VIB-VUB) and Eric Cox (UGent Faculty of Veterinary Medicine) have developed a new antibody technology that combines the advantages of antibody-based therapies with the convenience of oral drug administration. 

Edible antibodies to treat and prevent gastrointestinal disorders


Scientists have developed a new antibody technology that combines the advantages of antibody-based therapies with the convenience of oral drug administration. Importantly, these antibodies are manufactured using yeast in a process as straight-forward as food-manufacturing. This work is the result of an ongoing collaborative effort between Nico Callewaert (VIB-UGent Center for Medical Biotechnology), Ann Depicker (VIB-UGent Center for Plant Systems Biology), Henri De Greve (VIB-VUB Center for Structural Biology) and Eric Cox (UGent Faculty of Veterinary Medicine).